RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Halozyme Therapeutics Stock

Halozyme Therapeutics Employees 2024

Halozyme Therapeutics Employees

132

Ticker

HALO

ISIN

US40637H1095

WKN

A0DLHS

In 2024, Halozyme Therapeutics employed 132 people, a 0% change from the 132 number of employees in the previous year.

Halozyme Therapeutics Aktienanalyse

What does Halozyme Therapeutics do?

Halozyme Therapeutics Inc is a biotechnology company based in San Diego, California, specializing in the development of therapies for cancer and rare diseases. The company was founded in 1998 and has been listed on the NASDAQ since 2004. The business model of Halozyme is based on the use of the enzyme hyaluronidase, which helps distribute medications more quickly and effectively in the body. By using hyaluronidase, the absorption of medications can be improved, increasing their effectiveness and improving patient treatment. The company operates in three different areas: the first area is the development of its own therapies based on the use of hyaluronidase. Halozyme has several medications in the pipeline, including a therapy for pancreatic cancer and a treatment for muscular dystrophy. The second area is partnering with other pharmaceutical companies to enable faster absorption of their medications through the use of hyaluronidase. Halozyme has entered into over 30 partnerships with companies such as Pfizer, Roche, and Janssen. The third area is the development of diagnostic tools based on the analysis of protein-protein interactions. This technology is intended to accelerate the drug development process and support the selection of the most promising candidates. An example of a product developed by Halozyme in collaboration with a partner company is Herceptin SC (subcutaneous). Herceptin is a medication for the treatment of breast cancer that is typically administered intravenously. However, by adding hyaluronidase, the medication can also be administered subcutaneously, reducing treatment duration and patient burden. Halozyme aims to develop innovative therapies and accelerate the drug development process. By using hyaluronidase and partnering with other companies, the company can contribute to improving the effectiveness of medications and optimizing treatment outcomes for patients. Halozyme Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Halozyme Therapeutics's Employee Base

Halozyme Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Halozyme Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Halozyme Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Halozyme Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Halozyme Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Halozyme Therapeutics stock

How many employees does Halozyme Therapeutics have this year?

Halozyme Therapeutics has 132 undefined employees this year.

How many employees did Halozyme Therapeutics have compared to the previous year?

Compared to the previous year, Halozyme Therapeutics had 0% more employees.

What impact did the number of employees have on the company Halozyme Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Halozyme Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Halozyme Therapeutics?

The number of employees can also have an impact on investors of Halozyme Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Halozyme Therapeutics affect the company?

An increase in equity of Halozyme Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Halozyme Therapeutics's equity affect the company?

A reduction in equity of Halozyme Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Halozyme Therapeutics?

Some factors that can influence the equity of Halozyme Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Halozyme Therapeutics so important for investors?

The equity of Halozyme Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Halozyme Therapeutics influence the company?

The number of employees at Halozyme Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Halozyme Therapeutics evolved in recent years?

In recent years, the number of employees at Halozyme Therapeutics has changed by 0.

How many employees does Halozyme Therapeutics currently have?

Halozyme Therapeutics currently has 132 undefined employees.

Why is the number of employees important for investors of Halozyme Therapeutics?

The number of employees is important for investors of Halozyme Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Halozyme Therapeutics take to change the number of employees?

To change the number of employees, Halozyme Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Halozyme Therapeutics pay?

Over the past 12 months, Halozyme Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Halozyme Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Halozyme Therapeutics?

The current dividend yield of Halozyme Therapeutics is .

When does Halozyme Therapeutics pay dividends?

Halozyme Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Halozyme Therapeutics?

Halozyme Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Halozyme Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Halozyme Therapeutics located?

Halozyme Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Halozyme Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Halozyme Therapeutics from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Halozyme Therapeutics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Halozyme Therapeutics in the year 2023?

In the year 2023, Halozyme Therapeutics distributed 0 USD as dividends.

In which currency does Halozyme Therapeutics pay out the dividend?

The dividends of Halozyme Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Halozyme Therapeutics

Our stock analysis for Halozyme Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Halozyme Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.